BBIO: first_quarter 2024 lobbying report

{"url":"https://lda.gov/api/v1/filings/22a111ff-6b76-4e88-a98e-9a8355a9c62d/","filing_uuid":"22a111ff-6b76-4e88-a98e-9a8355a9c62d","filing_type":"1A","filing_type_display":"1st Quarter - Amendment","filing_year":2024,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/22a111ff-6b76-4e88-a98e-9a8355a9c62d/print/","filing_document_content_type":"text/html","income":null,"expenses":"160000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Amanda Malakoff","dt_posted":"2026-07-17T09:22:47-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3160 Porter Drive","registrant_address_2":"Suite 250","registrant_different_address":false,"registrant_city":"Palo Alto","registrant_state":"CA","registrant_zip":"94304","registrant":{"id":401107898,"url":"https://lda.gov/api/v1/registrants/401107898/","house_registrant_id":56231,"name":"BRIDGEBIO PHARMA, INC.","description":null,"address_1":"3160 Porter Drive","address_2":"Suite 250","address_3":null,"address_4":null,"city":"Palo Alto","state":"CA","state_display":"California","zip":"94304","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMANDA MALAKOFF","contact_telephone":"+1 202-543-8345","dt_updated":"2026-07-30T07:35:35.104836-04:00"},"client":{"id":57334,"url":"https://lda.gov/api/v1/clients/57334/","client_id":57334,"name":"BRIDGEBIO PHARMA, INC.","general_description":"Biotech company","client_government_entity":null,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-10-11"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Creating Hope Reauthorization Act of 2024 - H.R. 7384 Innovation in Pediatric Drugs Act - H.R. 6664 March-in/Bayh-Dole Act Orphan drug policies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144139,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MALAKOFF","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}